Biomea Fusion (BMEA) Price/FCF Ratio: History & Chart

Biomea Fusion, Inc.(BMEA)

Biotechnology · San Carlos, CA

$1.27-0.03 (-2.31%)

Delayed quote: Oct 6, 2026, 9:40 AM EDT

About Biomea Fusion, Inc.

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

San Carlos, CA

37 employees

biomeafusion.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael J. Hitchcock

View full financials

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Biomea Fusion, Inc. (BMEA)	$91.82M	N/A	N/A	N/A	N/A
electroCore, Inc. (ECOR)vs ›	$91.51M	N/A	N/A	N/A	N/A
Cardiff Oncology, Inc. (CRDF)vs ›	$88.63M	N/A	17.74	16.00	17.53
Equillium, Inc. (EQ)vs ›	$89.15M	N/A	24.77	24.77	24.77
Conexeu Sciences Inc. (CNXU)vs ›	$88.84M	N/A	N/A	N/A	N/A
ImmuCell Corporation (ICCC)vs ›	$88.52M	21.00	49.21	51.81	51.81
CareCloud, Inc. (CCLD)vs ›	$87.11M	4.02	5.32	4.50	8.18
Acrivon Therapeutics, Inc. Common Stock (ACRV)vs ›	$85.60M	N/A	N/A	N/A	N/A
Anixa Biosciences, Inc. (ANIX)vs ›	$99.48M	N/A	17.97	17.97	17.97
Atara Biotherapeutics, Inc. (ATRA)vs ›	$83.97M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

PRICE/FCF RATIO

TTM

Biomea Fusion, Inc. (BMEA)

$91.82M

N/A

electroCore, Inc. (ECOR)vs ›

$91.51M

N/A

Cardiff Oncology, Inc. (CRDF)vs ›

$88.63M